Overview

Naproxen Pharmacogenetic Study (Project 1, Aim 2)

Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
This is a mechanism-based study in healthy adults to determine the effect of the CYP2C9 M1L gene polymorphism on the functional activity of the encoded CYP2C9 enzyme towards the probe substrate naproxen. CYP2C9 activity will be evaluated by measurement of O-desmethyl naproxen and unchanged naproxen in 24-hour urine following administration of a single oral dose of naproxen (Aleve) in Yup'ik Alaska Native adult men and women who were previously determined in a separate observational study to be homozygous for the CYP2C9*1 allele or a carrier of the CYP2C9 M1L allele.
Phase:
Phase 4
Details
Lead Sponsor:
University of Washington
Collaborators:
National Institute of General Medical Sciences (NIGMS)
Oregon Health and Science University
Treatments:
Naproxen